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Background: Topotecan (TPT) is a therapeutic option for women with platinum-resistant or -refractory ovarian cancer.
However, the dose-limiting toxicity of TPT is myelosuppression. This led us to seek a combination treatment to augment
TPT anti-cancer activity in a cancer-targeted manner. Ovarian serous cancers, a major subtype, show dysregulated DNA
repair pathway and often display a high level of CHEK1 (CHK1), a cell cycle regulator and DNA damage sensor.
CHEK1 inhibitors are a novel approach to treatment, and have been used as single agents or in combination
chemotherapy in many cancers.
Methods: We evaluated the cellular effects of TPT in a panel of high grade serous (HGS) and non-HGS ovarian
cancer cells. We then determined IC50s of TPT in the absence and presence of CHEK1 inhibitor, PF477736. Synergism
between TPT and PF477736 was calculated based on cellular viability assays. Cytotoxic effect of the combined treatment
was compared with apoptotic activities by Caspase3/7 activity assay and Western blotting of cleaved-PARP1 and γH2AX.
Results: Non-HGS ovarian cancer cells were generally more sensitive to TPT treatment compared to HGS ovarian cancer
cells. When combined with CHEK1 inhibitor, TPT potently and synergistically inhibited the proliferation of HGS ovarian
cancer cells. This dramatic synergism in cellular toxicity was consistent with increases in markers of apoptosis.
Conclusions: Our findings suggest that the addition of CHEK1 inhibitor increases the response of ovarian cancer cells
to TPT. Furthermore, reduced dosages of both drugs achieved maximal cytotoxic effects by combining TPT with CHEK1
inhibitor. This strategy would potentially minimize side effects of the drugs for extended clinical benefit.
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Ovarian cancer consists of 4 major histologic subtypes
including serous, clear cell, endometrioid, and mucinous
[1]. Each harbors defining patterns of molecular aberra-
tions that could affect response to treatment and clinical
outcome. Most ovarian cancers are diagnosed at advanced
III or IV stage, and current standard of care includes sur-
gical cytoreduction and platinum-based chemotherapy.
Ovarian cancer has a high response rate, but most cancers
eventually relapse and metastasize, becoming resistant
and refractory to standard chemotherapy.
The most common subtype, high-grade serous (HGS)
ovarian cancer, is characterized by defective DNA repair* Correspondence: annunzic@mail.nih.gov
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unless otherwise stated.[2]. Treatment approaches commonly include chemo-
therapies that induce DNA damage, since the ovarian
cancer cell will die when it is incapable of recovering
from injury to its DNA. Platinum chemotherapies, the
hallmark of DNA damaging agents, have been combined
with other cancer drugs such as taxanes, which alter
microtubule function [3]. Topoisomerase I and II inhibitors,
such as camptothecin and etoposide, block DNA unwind-
ing during replication, transcription, and chromatin remod-
eling, by preventing the rejoining process of the DNA
strands and resulting in accumulation of DNA breaks. In
particular, the topoisomerase I inhibitor topotecan (TPT) is
active against many cancer types including platinum-
sensitive and resistant ovarian cancers [4,5]. Unfortunately,
side effects of TPT and other DNA-damaging agents in-
clude low blood counts, nausea, vomiting, diarrhea, andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sponses. These adverse events limit the dose that can be
administered and the duration of treatment. Ideally, com-
bination therapy with TPT should include agents that ex-
ploit defects in the cancer cells to augment tumor-specific
cell death without increasing intolerable adverse effects to
the patient.
Throughout the lifetime of a cell, DNA damage is in-
troduced either exogenously or endogenously. Cellular
sensing of DNA damage and its repair occur throughout
cell cycle checkpoints. For example, p53 is a main
checkpoint regulator in G1/S phase, while checkpoint
kinase 1/2 (CHEK1/2, CHK1/2) is crucial in S and G2/
M checkpoints. In HSG ovarian cancers, p53 is either
null or mutated, increasing the cellular dependency on
CHEK1/2 for DNA damage repair and survival. Support-
ing this notion, we recently showed that CHEK1 gene is
overexpressed in nearly all cases of HGS ovarian cancer
as compared to normal ovarian surface epithelium in
The Cancer Genome Atlas (TCGA) dataset, suggesting
that CHEK1 is required for cells to tolerate the defective
DNA repair intrinsic to HGS cancers [2,6]. Upon DNA
damage, CHEK1 is activated by ATR signaling and se-
quentially phosphorylated at residues S317 and S345
which subsequently induce autophosphorylation on
S296 to trigger cell cycle arrest and DNA repair [7]. In-
deed, recent studies suggested that both pS345 CHEK1
and pS296 CHEK1 could be used as pharmacodynamic
markers to monitor the CHEK1 inhibition upon treat-
ment with CHEK1 inhibitor alone and combination
treatments [8,9].
Inhibition of CHEK1/2 could therefore present a novel
therapeutic strategy. Cancer cells with dysfunctional p53
may be particularly susceptible to such drugs. CHEK in-
hibition would cause premature entry into mitosis without
adequate repair of DNA. This excessive DNA damage
would lead to mitotic catastrophe and subsequent cancer
cell death. For this reason, several CHEK1 inhibitors are
under development as single agents as well as a combined
therapy [10,11].
Since TPT is used as therapy for recurrent cisplatin
resistant and refractory ovarian cancer, and increased
expression levels of CHEK1 are observed in ovarian
cancers, we hypothesized that inhibiting CHEK1 could
be a means to enhance the anti-cancer activity of TPT
preferentially in ovarian cancer cells, thus increasing
their therapeutic index in cancer cells as compared to
normal tissues.Methods
Cell lines
Ovarian cancer cell lines, A2780, HeyA8, Igrov1, Skov3,
Ovcar5, Ovcar3, Ovcar8, OV90, PEO1 and PEO4 weremaintained in RPMI supplemented with 10% heat-
inactivated FBS and 1X Pen/Strep.
Chemical inhibitors
Stock solutions of Topotecan HCl (Selleck, S1231) and
PF477736 (Selleck, S2904) were prepared in DMSO and
aliquots were stored at −80°C.
XTT assay
Cells were seeded in 96-well plates at a density of 1–
2,000 cells/50 μl/well in triplicate. In general, the drug
was added 24 hours after seeding and XTT assay was
routinely performed in 3 days after drug treatment un-
less indicated. Cellular viability was assessed by incubat-
ing cultures with XTT freshly mixed with PMS (Sigma)
and absorbances were read in a Tecan plate reader (Re-
search Triangle Park, NC). Cellular proliferation was cal-
culated relative to experimental negative controls and
standard deviation was calculated from triplicates.
The cancer genome atlas data
TCGA ovarian cancer dataset was analyzed and ex-
tracted using a web-based tool (http://www.cbioportal.
org/public-portal/) [2].Western blot analysis
Total protein was extracted from OC cell lines with 1%
NP40 lysis buffer containing 150 mM NaCl, 50 mM
TrisHCl, 10% glycerol, 1 X Halt proteinase inhibitor
cocktail, 5 mM NaF, and 1 mM NaOrthovanadate. Pro-
tein concentrations were estimated using BCA Protein
Assay Kit (Thermo Scientific, Rockford, IL). The proteins
were separated on the NuPage 4–12% gel (Invitrogen,
Carlsbad, CA) and the band was visualized using either
Lumina Classico or Crescendo Western HRP substrate
system (Millipore) depending on the signal intensities.
Antibodies Chk1 G-4 (Santa Cruz, sc-8408), phospho-Chk1
Ser345 (Cell Signaling, #2348), phospho-Chk1 Ser296 (Cell
Signaling, #2349), cleaved PARP (Cell Signaling, #9541),
phospho-H2AX (Cell Signaling, #5438), Topoisomerase I
(Abcam, ab3825), and GAPDH (Millipore, MAB374) were
used in this study, and the secondary antibodies ECL
anti-rabbit IgG HRP and ECL anti-mouse IgG HRP
(GE Healthcare) were used at 1:5000 dilutions.
Caspase3/7 assay
Cells were seeded in 96-well white-walled plates at a
density of 2,000 - 5,000 cells/50 μl/well and the drug in
a 50 μl volume was added 24 hours after seeding. The
caspase activity was measured after 16 hours additional
incubation followed by adding 40 μl Caspase-Glo re-
agent (Promega) per well.
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Cells were seeded at 8 X 105/60 mm plate and 8 hours
prior to drug treatment. Fresh complete medium con-
taining 0.2 μM TPT, 0.5 μM PF477736, or both drugs
was added and cells were incubated for 16 hours. The
procedure was performed according to manufacturer’s
protocol (BD Pharmingen APC BrdU Flow kit). Follow-
ing 30 minutes incubation after adding BrudU, cells were
trypsinized and collected for subsequent fixation and
permeabilization. Cells were analyzed by FACS Calibur
(Becton Dickinson) after staining with APC-anti-BrdU
and 7-AAD. Cell cycle was analyzed using FlowJo
software.
Results
HGS ovarian cancer cells are more resistant to TPT
treatment than non-HGS cells
A recent study proposed HGS ovarian cancer model cell
lines based on the comparison of genomic profiles of
ovarian cancer cell lines with HGS ovarian tumors [12].
We initially determined cytotoxicity of TPT in a panel of
4 non-HGS, and 6 HGS ovarian cancer cell lines includ-
ing PEO1 and PEO4, a pair of HGS ovarian cancer cell
lines established from the same patient before and after
platinum-based chemotherapy [13]. In general, all HSG
ovarian cancer cells except PEO1 were more resistant to
TPT treatment compared to non-HGS ovarian cancer
cell lines (Figure 1A). When IC50 values were deter-
mined by CompuSyn software, PEO1 cells showed IC50
of less than 10 nM, comparable to those of non-HGS
ovarian cancer cells. Interestingly, OV90 and PEO4 were
the most resistant, showing approximately 50% of cellu-
lar viability even at 500 nM. Next, we investigated the
relationship between the expression levels of Topoisom-
erase I and the sensitivities to TPT among these ovarian
cancer cell lines. At steady-state levels, both non-HGS
and HGS cell lines showed similar levels of topoisomer-
ase I (Figure 1B). This suggests that the steady state level
of topoisomerase cannot predict the sensitivity to TPT.
Nonetheless, HGS ovarian cancer cells were generally
less sensitive to TPT treatment than non-HGS ovarian
cancer cells.
TOP1 is altered in a subset of ovarian serous tumors with
an association with a poor overall survival
In TCGA, ovarian cancer patient samples showed alter-
ations in the gene for topoisomerase I, TOP1 [2]. Thirty
five cases out of 316 ovarian serous cancer contained
TOP1 alterations including 1 amplification, 1 mutation,
and 33 mRNA dysregulations (Figure 2A). These alterations
were significantly associated with a worse overall survival
compared to the cases without alterations (Figure 2B).
Interestingly, 9 cases showed down-regulation of TOP1
mRNA. We also searched the mutation status of TOP1gene in the Cancer Cell Line Encyclopedia (CCLE) [14] and
found no alterations of TOP1 in 51 ovarian cancer cell
lines, but identified 29 mutations among over 1000 cancer
cell lines in that dataset (Additional file 1: Table S1). While
TOP1 mutations were rare in ovarian cancer cell lines and
tumors, a subset of ovarian cancers had dysregulated ex-
pression levels of TOP1. The correlation with poor survival
suggests a mechanism of resistance to DNA damaging
chemotherapy, since the patient tumors were taken at the
time of initial diagnosis. These alterations could similarly
serve as a biomarker for poor clinical response to TPT.
Therefore, we proceeded to identify compounds that would
increase the anti-cancer activity of TPT in HGS ovarian
cancer cells.
Co-treatment of TPT and PF477736 synergistically kills
ovarian cancer cells
Since HGS ovarian cancer cells required higher concen-
trations of TPT than non-HGS cells, we sought to iden-
tify a combination that achieved maximal cytotoxic
effect with a minimal dose of TPT. We previously found
that CHEK1 was overexpressed in most HGS ovarian
cancers [6], and hypothesized that inhibition of CHEK1
would increase the therapeutic index of TPT, given its
importance in DNA damage repair pathways. Therefore,
we investigated whether CHEK1 inhibitor, PF477736,
sensitized HGS ovarian cancer cell lines to TPT treat-
ment. PF477736 is a selective ATP-competitive inhibitor
that can enhance the antitumor activity of gemcitabine
[15]. First, the IC50 values of PF477736 were determined
by XTT assays. All 6 cell lines showed decreases in cellu-
lar viabilities in a dose dependent manner with a range
of IC50 78–375 nM (Figure 3A). We found no clear re-
lationship between total CHEK1 protein level and sensi-
tivity to CHEK1 inhibitor (Figure 3B); most HGS cell
lines, however, expressed abundant levels of CHEK1. Of
note, ovarian cancer cell lines used in this study express
either mutated or no p53, except A2780 (p53 wt). Specif-
ically, Ovcar5 and Skov3 do not express p53, while
HeyA8, Igrov1, Skov3, Ovcar3, Ovcar8, Ovcar90, PEO1
and PEO4 express mutant p53. Therefore, CHEK1 in-
hibitor sensitivity is not correlated with the status of p53
in ovarian cancer cell lines. With sub-lethal concentra-
tions of CHEK1 inhibitor indicated in Figure 3A (*), the
dose–response to TPT was significantly shifted in 6
HGS ovarian cancer cell lines. The range of IC50 was
from 9.4 nM to 589 nM in the absence of PF477736,
and shifted downward more than 10-fold (between 0.2
nM to 23.6 nM) when CHEK1 activity was inhibited
(Figure 3C). Synergism between CHEK1 inhibitor and
TPT was calculated using a 6 X 6 matrix format with 2-
fold serial dilutions of both drugs at a 1:2 ratio of TPT:
PF (Table 1). Combination Index (CI) values below 1
were achieved in all cell lines, indicating synergism
Figure 1 (See legend on next page.)
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Figure 1 Pharmacological inhibition of Topoisomerase I in ovarian cancer cell lines. A. TPT toxicities were measured by XTT assay. Cells
were seeded at 1000 cells/well in 50 μl and 3 replicates 16–20 hours prior to the addition of the drug. XTT assay was performed 3 days later
upon drug treatment. The viability was calculated relative to no drug treatment and the error bars represent standard deviations calculated from
3 replicates. Shown is a representative of 2 – 5 independent experiments depending on cell lines. IC50 values were calculated by CompuSyn after
converting relative viability values to fraction affected numbers. B. The expression level of Topoisomerase I was examined using total lysates by
Western blotting. GAPDH was used as a loading control.
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highly sensitive to single treatment with either TPT or
PF477736 (Figure 1A, Figure 3A), the maximal com-
bined cytotoxicity was achieved at concentrations 2 or 4
fold less than in other cell lines (with 63 nM of TPT and
125 nM of PF477736). Although TPT combination with
CHEK1 inhibitor decreased TPT IC50 values by 30- and
25-fold, respectively, in OV90 and PEO4 cells, complete
cytotoxicity was not achieved (Figure 3C). When plotted
at a minimal cytotoxic concentration of TPT (15.6 nM),
cell survival was generally further decreased when com-
bined with the indicated sub-lethal concentrations of
CHEK1 inhibitor (Figure 3D). In order to examine
whether PF477736 also potentiates TPT activity in non-HGS
cells, we measured the cytotoxicity in Igrov1 cells upon
co-treatment with PF477736 and TPT using lower concen-
trations of both inhibitors than in HGS cells (Figure 3E).
As expected, the IC50 of TPT was decreased from 30 to
10.6 nM in the presence of 15.6 nM of PF477736, although
the potentiation was not as dramatic as in HGS ovarian
cancer cells.
We next investigated whether the order of drug ad-
ministration (sequential or simultaneous) affected the
synergism achieved with TPT and PF477736. Ovarian
cancer cells were treated with two drugs simultaneouslyFigure 2 Analysis of TOP1 in TCGA dataset. A. TOP1 alterations
including copy number, mutation, and mRNA expression were
examined. B. Overall survival analysis based on TOP1 alterations was
extracted from TCGA data analysis.or sequentially, either 24 or 48 hours apart. In general,
simultaneous treatment was more effective than sequen-
tial exposure, regardless of the order of dosing, treatment
duration or time of exposure (Figure 4). Overall, com-
bined simultaneous treatment with TPT and PF477736
synergistically killed ovarian cancer cells.Co-treatment with TPT and CHEK1 inhibitor increases
apoptosis and DNA damage response
Given the known mechanisms of each drug, we next
measured apoptosis and DNA damage response upon
single and dual exposure. Caspases 3 and 7 are activated
in the final stages of apoptosis and cleave PARP. As ex-
pected, caspase3/7 activity was consistently the most ele-
vated by combined treatment with TPT and PF477736
(Figure 5A). Cleaved PARP-1 level, a marker of late
apoptosis, was increased accordingly (Figure 5B). DNA
damage is indicated by phosphorylation of H2AX, and
this γ-phosphorylation was increased most highly with
combination treatment in all cell lines (Figure 5B). Each
agent alone and co-inhibition triggered CHEK1 S345
phosphorylation. TPT treatment significantly induced
CHEK1 S296 autophosphorylation, a marker for CHEK1
activity, but the autophosphorylation was clearly decreased
upon PF477736 alone and combination treatments. Total
CHEK1 level was decreased upon PF477736 alone and co-
inhibition, and total topoisomerase I level was decreased
upon TPT alone and co-inhibition (Figure 5B). In sum-
mary, DNA damage was greatest with co-treatment in all
6 cell lines, and the activation of CHEK1 activity upon
TPT treatment was abrogated by co-treatment with
PF477736. CHEK1 activation upon TPT treatment may
potentially provide the resistance and relapse to TPT
monotherapy especially in CHEK1-overexpressing HGS
ovarian cancer patients.
We also performed cell cycle analysis in both p53 null
(Ovcar5) and p53 mutant (Ovcar8) cell lines to investi-
gate whether inhibition of CHEK1 with PF477736 affects
TPT-induced cell cycle arrest. In both cell lines, we ob-
served that PF477736 abrogated TPT-induced cell cycle
arrest (Figure 5C).
Taken together, co-treatment with TPT and PF477736
more potently induced DNA damage and apoptosis than
either single treatment alone in ovarian cancer cells.
Figure 3 Cytotoxicity of TPT was increased in the presence of CHEK1 inhibitor. A. IC50 values of CHEK1 inhibitor (PF477736) were
determined by XTT assay done in 3 days upon treatment in 3 replicates. (*) indicates the concentrations used in Figure 3C. B. Western blot
analysis of total CHEK1 was done using total protein lysates. GAPDH was used as a loading control. The band intensity was quantified by ImageJ
and CHEK1 level was normalized by GAPDH. The CHEK1 levels in different cell lines were calculated relative to that of Ovcar5. IC50 values and
relative CHEK1 levels were plotted to examine their relationships by Microsoft Excel. C-E. XTT assays were done in the absence and presence of
CHEK1 inhibitor in 3 replicates and Fa (fraction affected), fraction of dead cells, was calculated from XTT assay. TPT IC50 values were calculated by
CompuSyn software.
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We recently found that CHEK1 gene was overexpressed
in most of HGS ovarian cancer, and combined inhibition
of pro-survival modulator, IKKε, cooperatively induced
apoptosis in ovarian cancers [6]. In this study, we have fur-
ther extended this finding to evaluate CHEK1 inhibitor-
based combination therapy. TPT is currently used for thesalvage treatment of ovarian cancer, but myelosuppression
is the dose-limiting toxicity. High doses of TPT are poorly
tolerated, resulting in treatment delays or dose reductions.
Therefore, we hypothesized that combining TPT with
CHEK1 inhibitor may be an effective and feasible ap-
proach to maximize the therapeutic index between cancer
cells and normal, allowing lower doses of both agents in
Table 1 Combination index (CI) values of topotecan and PF477736 co-treatment in ovarian cancer cells
Total Dose (uM) Ovcar5 Ovcar3 Ovcar8 OV90 PEO1 PEO4
TPT + PF Fa CI Fa CI Fa CI Fa CI Fa CI Fa CI
0.25 + 0.5 0.84 1.4 0.86 0.9 0.87 1.6 0.71 1.2 0.85 1.9 0.64 1.3
0.125 + 0.25 0.79 0.9 0.83 0.5 0.83 0.9 0.67 0.9 0.84 1.1 0.60 0.8
0.063 + 0.125 0.70 0.6 0.73 0.5 0.74 0.5 0.60 0.7 0.81 0.7 0.54 0.5
0.032 + 0.063 0.47 0.7 0.76 0.2 0.68 0.3 0.54 0.5 0.77 0.5 0.42 0.4
Fa (Fraction affected) was calculated from XTT assays and Fa value of greater than 0.8 is cytotoxic considering the detectable limit of XTT assay. Cellular killing
was examined under light microscope before measuring the viability. Synergistic CI values with Fa values are shown in bold.
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found that HGS ovarian cancer cell lines generally required
higher concentrations of TPT, in the absence of CHEK1 in-
hibition, to achieve equivalent cytotoxicity compared to
non-HGS ovarian cancer cell lines. When combined with
CHEK1 inhibitor (PF477736), TPT synergistically produced
maximal cytotoxic effects at reduced dosages.
Based on its mechanism of action, it has been hypothe-
sized that CHEK1 inhibition would potentiate the effectsFigure 4 Simultaneous treatment with TPT and PF477736 was
generally more potent than sequential treatments of individual
drugs. Treatment schedules of 24 (A) and 48 (B) hours apart
between drugs are shown. The concentrations of TPT and PF477736
were 10 nM and 0.1 μM, respectively, except Ovcar5 (0.3 μM
PF477736). Cellular viability was measured by XTT assay in 3
replicates and calculated relative to untreated cells.of standard chemotherapy in a wide range of cell lines. In
particular, CHEK1 inhibitors (e.g. V158411, AZD7762,
MK-8776, GNE-900, CCT244747) have been combined
with camptothecin and non-camptothecin inhibitors of
topoisomerases [8,16-19]. While combined inhibitions
generally showed synergistic effects, a study showed lim-
ited increase in cancer cell death with MK8776, reporting
that CHEK1 depletion with siRNA or inhibition with MK-
8776 only minimally sensitized Ovcar8 cells to TPT in
colony formation assays [17]. Combination of GNE-900
and camptothecin was minimally effective than either
alone in vivo xenograft model [18]. The reasons for this
discrepancy may be due to different potency and pene-
trance of CHEK1 inhibitors as well as different measure-
ments in biological assays.
Our current study provides insight into the nuances of
how the combination of CHEK1 and topoisomerase in-
hibition may be most effectively used. Not all ovarian
cancer cell lines were equally sensitive to either agent
alone or in combination. Our data demonstrate that
these agents may have the most therapeutic potential in
HGS ovarian cancers, where the combination demon-
strated the greatest degree of synergy. In addition, the
order of drug administration was relevant, with the most
cell death occurring when both drugs were given to-
gether, or when TPT was given first, followed by
PF477736. Interestingly, the least effective sequence was
administering PF477736 prior to TPT. Similarly, a study
using CHEK1 inhibitor AZD7762 showed that gemcita-
bine administration either concurrent with or before
AZD7762 resulted in maximal chemosensitization in
pancreatic cancer model [9].
Several CHEK1 inhibitors (PF477736, MK-8776/
SCH900776, and LY2606368) have completed phase 1
evaluation as single agents, but formal reports are not
available. In addition, PF477736 (Pfizer) was evaluated in
advanced solid tumors in combination with gemcitabine
(NCT00437203) and was discontinued from develop-
ment. CHEK1 inhibitor MK8776 (Merck) in combin-
ation with gemcitabine has also reported phase 1
evaluation in patients with solid tumors. Combining an
anti-metabolite (gemcitabine) with MK8776 was well
tolerated with few patients experiencing grade 3–4
Figure 5 Combined treatment with TPT and PF477736 showed increased apoptotic activities and DNA damage. A. Apoptotic activity was
measured by Caspase3/7 activity assay. Cells were treated with TPT and/or PF477736 for 16 hours with indicated drug concentrations and
Caspase3/7 activity was measured relative to untreated samples in triplicates. B. Cells were treated at the same concentrations as in Caspase3/7
assay for 16 or 24 hours and total cell lysates were prepared for Western blotting. GAPDH was used as a loading control. C. Eight hundred
thousand cells were plated in 60 mm plates 8 hours prior to drug treatment. Cells were treated for 16 hours with TPT (0.2 μM) and/or PF
(0.5 μM). G0/G1, S, and G2/M phases were measured based on staining of APC-BrdU and 7-AAD by flow cytometry. Cell cycle was analyzed by
FlowJo software.
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(15%) [20].
TPT has been combined clinically with angiogenesis
inhibitors bevacizumab or trabananib [21,22]. Such a
strategy combines agents targeting two separate path-
ways (DNA replication and angiogenesis) important to
cancer, without overlapping side effects so as not to limit
dosage of either drug. The combination of TPT with
CHEK1 inhibitor takes a different approach, by targeting
a potential mechanism of resistance to TPT, the upregulated
DNA repair by overexpressed CHEK1. This approach poten-
tially widens the therapeutic index by preferentially targeting
the ovarian cancer-specific dependence on upregulated oractivated CHEK1, and allowing increased cancer cell killing
at lower doses of each drug. In the future, it may also be pos-
sible to incorporate anti-angiogenic agents as well, due to
non-overlapping toxicities.
Disrupting DNA repair mechanisms after DNA dam-
aging chemotherapy is a strategy that we have used clin-
ically [23]. Carboplatin was given to induce DNA breaks,
and the PARP inhibitor olaparib was administered in
order to block repair of single-strand breaks, which pro-
gressed to double-strand breaks during DNA replication,
causing cell death. This strategy was designed with the
goal of achieving a higher therapeutic index in ovarian
cancer cells known to harbor defective DNA repair
Kim et al. BMC Cancer  (2015) 15:196 Page 9 of 10pathways, particularly in cancers with BRCA mutations.
Additionally, the increased potency was attained with re-
duced doses of each drug. In our current study, we
achieved the same phenomenon in vitro, by co-treating
with CHEK1 inhibitor and TPT. This combination syn-
ergistically inhibited cellular proliferation at sub-lethal
concentrations for each drug given alone. The cytotoxic
synergism was accordingly reflected in apoptotic activ-
ities and DNA damage response. Interestingly, we found
that OV90 and PEO4 cells were resistant to TPT alone,
and co-inhibition with TPT and PF477736 resulted in
achieving equivalent cellular toxicity with reduced doses
of both drugs. However, this co-inhibition still failed to
attain complete cellular toxicity in OV90 and PEO4.
Further studies are required to know why these two cell
lines were so resistant to TPT and even to the co-
treatment.
BRCA-mutated cancers tend to have the highest re-
sponse rates to DNA damaging agents in general. In-
deed, our results confirm that the BRCA-mutated cell
line PEO1 was the most sensitive of HGS cancers to
treatment with TPT or CHEK1 inhibitor alone. Most
HGS ovarian cancers, however, do not have BRCA mu-
tations, but do have elevated expression of CHEK1.
Thus, combination therapy of CHEK1 inhibitor with
DNA damaging agents such as TPT could introduce an
analogous strategy for targeting non-BRCA mutated or
BRCA-like HGS ovarian cancers.
Another potential marker for potency to CHEK1 in-
hibitor may be its autophosphorylation. Decreased levels
of CHEK1 S296 autophosphorylation have been corre-
lated with response to CHEK1 inhibition in colon,
breast, and ovarian cancer cell lines [8,24]. As shown in
this study, this marker is expressed in HGS ovarian cancer
cell lines at steady states and CHEK1 gene is over-
expressed in nearly all cases of TCGA HGS ovarian cancers
[6]. Therefore, this marker should be evaluated at the time
of initial diagnosis and in the course of treatment, specific-
ally in recurrent HGS ovarian cancers.
We are currently conducting a phase 2 clinical trial
testing single agent CHEK1 inhibitor LY2606368 in
women whose cancers are likely to have defects in DNA
repair (NCT02203513). The trial will study 3 cohorts of
cancers: BRCA-mutated, HGS ovarian cancer, and
TNBC. We hypothesize that these types of cancers will
be susceptible to CHEK1 inhibition due to their poor
ability to repair double strand DNA breaks. The adverse
events in this trial have not yet been analyzed. Among
many CHEK1 inhibitors under clinical evaluation, an
ideal CHEK1 inhibitor to use with TPT for combination
treatment would exhibit minimal overlap in toxicity such
as myelosuppression. Based on our data, however, it is
possible that the anti-cancer effect of the combination
will be achieved at lower doses of both agents, whichwould allow for safe administration of these two drugs,
specifically targeted to patients with HGS ovarian cancer.
Conclusions
Our study shows that TPT synergistically induces cyto-
toxicity in combination with CHEK1 inhibitor especially
in HGS ovarian cancer cells.
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